- Home
- LRE vs MIST Comparison
LRE vs MIST Comparison
Compare LRE & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRE | MIST |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Japan | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 176.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LRE | MIST |
|---|---|---|
| Price | $1.49 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 61.8K | ★ 4.1M |
| Earning Date | 07-30-2015 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $0.63 |
| 52 Week High | $2.97 | $3.06 |
Technical Indicators
Market Signals| Indicator | LRE | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 43.40 |
| Support Level | $1.40 | $1.97 |
| Resistance Level | $1.69 | $2.13 |
| Average True Range (ATR) | 0.18 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 40.00 | 31.25 |
Price Performance
Historical ComparisonAbout LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).